title: Improving the efficacy of antibody-based cancer therapies.
abstract: A quarter of a century after their advent, monoclonal antibodies have become the most rapidly expanding class of pharmaceuticals for treating a wide variety of human diseases, including cancer. Although antibodies have yet to achieve the ultimate goal of curing cancer, many innovative approaches stand poised to improve the efficacy of antibody-based therapies.
authors.affiliation: Immunex, Seattle, Washington 98101, USA. carterp@immunex.com
authors.forename: P
authors.initials: P
authors.lastname: Carter
mesh_terms: D000818:Animals; D000906:Antibodies / Q000276:immunology / Q000627:therapeutic use*; D018033:Antibodies, Bispecific / Q000627:therapeutic use; D000911:Antibodies, Monoclonal / Q000276:immunology / Q000627:therapeutic use; D061067:Antibodies, Monoclonal, Humanized; D058846:Antibodies, Monoclonal, Murine-Derived; D000912:Antibodies, Neoplasm / Q000276:immunology / Q000627:therapeutic use; D000920:Antibody-Dependent Cell Cytotoxicity; D000951:Antigens, Neoplasm / Q000276:immunology; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D017322:Clinical Trials, Phase II as Topic; D017326:Clinical Trials, Phase III as Topic; D003131:Combined Modality Therapy; D016207:Cytokines / Q000008:administration & dosage / Q000627:therapeutic use; D016503:Drug Delivery Systems; D006801:Humans; D007116:Immunization, Passive; D018796:Immunoconjugates / Q000627:therapeutic use; D007167:Immunotherapy / Q000379:methods; D000922:Immunotoxins / Q000627:therapeutic use; D008081:Liposomes; D051379:Mice; D009363:Neoplasm Proteins / Q000037:antagonists & inhibitors / Q000276:immunology; D018365:Neoplasm, Residual; D009369:Neoplasms / Q000188:drug therapy / Q000276:immunology / Q000473:pathology / Q000532:radiotherapy / Q000628:therapy*; D009389:Neovascularization, Pathologic / Q000276:immunology / Q000628:therapy; D011355:Prodrugs / Q000008:administration & dosage; D015202:Protein Engineering; D016499:Radioimmunotherapy; D011993:Recombinant Fusion Proteins / Q000276:immunology / Q000627:therapeutic use; D000069283:Rituximab; D000068878:Trastuzumab; D016896:Treatment Outcome; D023041:Xenograft Model Antitumor Assays
chemical_list: D000906:Antibodies; D018033:Antibodies, Bispecific; D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D058846:Antibodies, Monoclonal, Murine-Derived; D000912:Antibodies, Neoplasm; D000951:Antigens, Neoplasm; D016207:Cytokines; D018796:Immunoconjugates; D000922:Immunotoxins; D008081:Liposomes; D009363:Neoplasm Proteins; D011355:Prodrugs; D011993:Recombinant Fusion Proteins; D000069283:Rituximab; D000068878:Trastuzumab